Sirolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.708
CATDS
0.023
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Sirolimus. Strongest target: ERN1_IRE1 at 31.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERN1_IRE1 | 31.9% | 68.1% |
| 2 | CAMKK2 | 30.4% | 69.6% |
| 3 | PKMYT1 | 29.5% | 70.5% |
| 4 | PDK2_PDHK2 | 26.8% | 73.2% |
| 5 | WNK1 | 24.1% | 75.9% |
| 6 | STK21_CIT | 23.1% | 76.9% |
| 7 | MUSK | 22.9% | 77.1% |
| 8 | GSK3A | 22.3% | 77.7% |
| 9 | STK33 | 20.6% | 79.4% |
| 10 | PHKG1 | 19.8% | 80.2% |
| 11 | EGFR | 18.0% | 82.0% |
| 12 | CTK_MATK | 17.9% | 82.1% |
| 13 | MLK3_MAP3K11 | 17.8% | 82.2% |
| 14 | TTBK2 | 16.0% | 84.0% |
| 15 | SLK_STK2 | 15.6% | 84.4% |
| 16 | STK39_STLK3 | 14.9% | 85.1% |
| 17 | SSTK_TSSK6 | 14.7% | 85.3% |
| 18 | TTBK1 | 14.2% | 85.8% |
| 19 | BMPR2 | 13.8% | 86.2% |
| 20 | KSR2 | 13.2% | 86.8% |
Selectivity landscape
Where Sirolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Sirolimus.
Annotations
Sign in to read and post annotations.
Loading…